Document:

Form of Subscription Agreement dated September 1, 2009

 Exhibit 10.1 
 Set forth below is a list of each of the investors that executed a Subscription Agreement, in the form attached hereto, with Casual Male Retail Group, Inc. (the “Company”), the number of shares of the Company’s common stock
to be purchased by such investor and the aggregate purchase price to be paid by such investor for such shares: 
  

						
	 Investor
	  	Shares	  	Aggregate Purchase Price
	 Fidelity Capital Trust: Fidelity Small Cap Independence Fund
	  	1,500,000	  	$	4,125,000.00
			
	 Variable Insurance Products Fund III: Value Strategies Portfolio
	  	81,755	  	$	224,826.25
			
	 Fidelity Advisor Series I: Fidelity Advisor Value Strategies Fund
	  	275,245	  	$	756,923.75
			
	 Fidelity Securities Fund: Fidelity Small Cap Growth Fund
	  	750,000	  	$	2,062,500.00
			
	 Fidelity Trend Fund: Fidelity Trend Fund
	  	550,000	  	$	1,512,500.00
			
	 Fidelity Advisor Series I: Fidelity Advisor Strategic Growth Fund
	  	10,000	  	$	27,500.00
			
	 Variable Insurance Products Fund IV: Growth Stock Portfolio
	  	10,000	  	$	27,500.00
			
	 Variable Insurance Products Fund III: Balanced Portfolio
	  	154,000	  	$	423,500.00
			
	 Fidelity Securities Fund: Fidelity Dividend Growth Fund
	  	1,424,000	  	$	3,916,000.00
			
	 Fidelity Advisor Series: Fidelity Advisor Dividend Growth Fund
	  	195,000	  	$	536,250.00

 FORM OF SUBSCRIPTION AGREEMENT 
 Casual Male Retail Group, Inc. 
 555 Turnpike Street 
 Canton, Massachusetts 02021 
 Gentlemen: 
 The undersigned (the “Investor”) hereby confirms its agreement with Casual Male Retail Group, Inc., a Delaware corporation (the “Company”), as follows: 
 1. This Subscription Agreement, including the Terms and Conditions for Purchase of Shares attached hereto as Annex I (collectively, this
“Agreement”) is made as of the date set forth below between the Company and the Investor. 
 2. The Company has
authorized the sale and issuance to certain investors of up to an aggregate of 4,950,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (the “Common Stock”), for a purchase price of $2.75 per
share (the “Purchase Price”). 
 3. The offering and sale of the Shares (the “Offering”) are being
made pursuant to (a) an effective Registration Statement on Form S-3 (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”), including the Prospectus
contained therein (the “Base Prospectus”), (b) if applicable, certain “free writing prospectuses” (as that term is defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities
Act”)), that have been or will be filed with the Commission and delivered to the Investor on or prior to the date hereof (the “Issuer Free Writing Prospectus”), containing certain supplemental information regarding the
Shares, the terms of the Offering and the Company, and (c) a Prospectus Supplement (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”) containing certain supplemental
information regarding the Shares and terms of the Offering that has been or will be filed with the Commission and delivered to the Investor (or made available to the Investor by the filing by the Company of an electronic version thereof with the
Commission). 
 4. The Company and the Investor agree that the Investor will purchase from the Company and the Company will issue
and sell to the Investor the Shares set forth below for the aggregate purchase price set forth below. The Shares shall be purchased pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex I and incorporated herein
by this reference as if fully set forth herein. The Investor acknowledges that the Offering is not being underwritten and that there is no minimum offering amount. 
 5. The manner of settlement of the Shares purchased by the Investor shall be determined by such Investor as follows (check one): 
  

					
	 [    ]
	  	A.	  	Delivery by crediting the account of the Investor’s prime broker (as specified by such Investor on Exhibit A annexed hereto) with the Depository Trust Company
(“DTC”) through its Deposit/Withdrawal At Custodian (“DWAC”) system, whereby Investor’s prime broker shall initiate a DWAC transaction on the Closing Date using its DTC participant identification number, and
released by American Stock Transfer & Trust Company, the Company’s transfer agent (the “Transfer Agent”), at the Company’s direction. NO LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS
AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR SHALL:
			
		  		  	 (I)     DIRECT THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE CREDITED WITH THE SHARES ARE MAINTAINED TO
SET UP A DWAC INSTRUCTING THE TRANSFER AGENT TO CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE SHARES, AND

					
		  		  	 (II)    REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE PRICE FOR THE SHARES BEING PURCHASED
BY THE INVESTOR TO THE FOLLOWING ACCOUNT:

			
		  		  	 Bank of America
 Address:
 ABA # 
 Account Name: 
 Account Number: 
 Attention: 
 Phone: 
 Facsimile: 

	
	— OR —
			
	 [    ]
	  	B.	  	Delivery versus payment (“DVP”) through DTC (i.e., on the Closing Date, the Company shall deliver Shares registered in the Investor’s name and address as set
forth below and released by the Transfer Agent to the Investor through DTC at the Closing directly to the account(s) at an institution (the “Institution”) identified by the Investor; upon receipt of such Shares, the
Institution shall promptly electronically deliver such Shares to the Investor, and simultaneously therewith payment shall be made by the Institution by wire transfer to the Company). NO LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS
AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR SHALL:
			
		  		  	 (I)     NOTIFY THE INSTITUTION OF THE ACCOUNT OR ACCOUNTS AT THE INSTITUTION TO BE CREDITED WITH THE SHARES BEING
PURCHASED BY SUCH INVESTOR, AND

			
		  		  	 (II)    CONFIRM THAT THE ACCOUNT OR ACCOUNTS AT THE INSTITUTION TO BE CREDITED WITH THE SHARES BEING PURCHASED BY THE
INVESTOR HAVE A MINIMUM BALANCE EQUAL TO THE AGGREGATE PURCHASE PRICE FOR THE SHARES BEING PURCHASED BY THE INVESTOR.

 IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR CONFIRM THE PROPER
ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF DWAC OR DVP IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE SHARES OR DOES NOT MAKE PROPER ARRANGEMENTS FOR SETTLEMENT IN A
TIMELY MANNER, THE SHARES MAY NOT BE DELIVERED AT CLOSING TO THE INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE CLOSING ALTOGETHER. 
 6. The Investor represents that, except as set forth below, (a) it has had no position, office or other material relationship within the past three years with the Company or persons known to it to be affiliates of the Company,
(b) it is not a FINRA member or an Associated Person (as such term is defined under the NASD Membership and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor nor any group of investors (as
identified in a public filing made with the Commission) of which the Investor is a part in connection with the Offering of the Shares, acquired, or obtained the right to acquire, 20% or more of the Common Stock (or securities convertible into or
exercisable for Common Stock) or the voting power of the Company on a post-transaction basis. Exceptions: 
 The Investor is an Associated Person of certain
FINRA members, none of which are involved in this Offering. 
  

 - 2 - 

 7. The Investor represents that it has received (or otherwise had made available to it by the
filing by the Company of an electronic version thereof with the Commission) the Base Prospectus which is a part of the Company’s Registration Statement, the documents incorporated by reference therein and any free writing prospectus
(collectively, the “Disclosure Package”), prior to or in connection with the receipt of this Agreement. The Investor acknowledges that, prior to the delivery of this Agreement to the Company, the Investor will receive certain
additional information regarding the Offering, including pricing information (the “Offering Information”). Such information may be provided to the Investor by any means permitted under the Securities Act, including the Prospectus
Supplement, a free writing prospectus and oral communications. 
 8. No offer by the Investor to buy Shares will be accepted and no
part of the Purchase Price will be delivered to the Company until the Investor has received the Offering Information and the Company has accepted such offer by countersigning a copy of this Agreement, and any such offer may be withdrawn or revoked,
without obligation or commitment of any kind, at any time prior to the Company sending (orally, in writing or by electronic mail) notice of its acceptance of such offer. An indication of interest will involve no obligation or commitment of any kind
until the Investor has been delivered the Offering Information and this Agreement is accepted and countersigned by or on behalf of the Company. 
 [Remainder of Page Left Blank Intentionally. Signature Page Follows.] 
  

 - 3 - 

 Number of Shares: 
 Purchase
Price Per Share: $2.75 
 Aggregate Purchase Price: 
 Please
confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose. 
  

			
	Dated as of: September 1, 2009
	
	  

	INVESTOR
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	Agreed and Accepted this 1st day of September, 2009:
	
	CASUAL MALE RETAIL GROUP, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 - 4 - 

 ANNEX I 
 TERMS AND CONDITIONS FOR PURCHASE OF SHARES 
 1. Authorization and Sale of the Shares. Subject
to the terms and conditions of this Agreement, the Company has authorized the sale of the Shares. 
 2. Agreement to Sell and Purchase the
Shares. 
 2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor, and the Investor will
purchase from the Company, upon the terms and conditions set forth herein, the number of Shares set forth on the last page of the Agreement to which these Terms and Conditions for Purchase of Shares are attached as Annex I (the
“Signature Page”) for the aggregate purchase price therefor set forth on the Signature Page. 
 2.2 The Company
proposes to enter into substantially this same form of Subscription Agreement with certain other investors (the “Other Investors”) and expects to complete sales of Shares to them. The Investor and the Other Investors are hereinafter
sometimes collectively referred to as the “Investors,” and this Agreement and the Subscription Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.”

 2.3 The Investor acknowledges that its decision to enter into this Agreement has been made by such Investor independently of any
Other Investor. The Investor acknowledges that nothing contained herein, and no action taken by any Investor pursuant to the Agreements, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind
of entity, or create a presumption that the Investors are in any way acting in concert with respect to their investments or obligations hereunder. 
 3. Closings and Delivery of the Shares and Funds. 
 3.1 Closing. The closing (the “Closing”)
of the purchase of the Shares by the Investor shall occur at the offices of Greenberg Traurig, LLP, One International Place, Boston, Massachusetts 02110. The date and time of the Closing (the “Closing Date”) shall be 10:00 a.m.,
Boston time, on the first (1st) business day on which the conditions to the Closing set forth in Section 3.2 below are satisfied or waived (or such later date as is mutually agreed to by the Company and the Investor). At the Closing,
(a) the Company shall cause the Transfer Agent to deliver to the Investor the number of Shares set forth on the Signature Page registered in the name of the Investor or, if so indicated on the Investor Questionnaire attached hereto as
Exhibit A, in the name of a nominee designated by the Investor and (b) the aggregate purchase price for the Shares being purchased by the Investor will be delivered by or on behalf of the Investor to the Company. 
 3.2 Conditions to the Obligations of the Parties. 
 (a) Conditions to the Company’s Obligations. The Company’s obligation to issue and sell the Shares to the Investor shall be subject to: 
 (i) the Company’s receipt of the Investor’s executed signature page to this Agreement; 
  

 - 5 - 

 (ii) the receipt by the Company of the purchase price for the Shares being purchased hereunder as set
forth on the Signature Page; 
 (iii) the accuracy of the representations and warranties made by the Investor and the fulfillment of those
undertakings of the Investor to be fulfilled prior to the Closing Date; 
 (iv) the Company shall have obtained all governmental, regulatory
or third party consents and approvals, if any, necessary for the sale of the Shares, including without limitation, those required by the NASDAQ Global Select Market (“Nasdaq”); 
 (v) no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court
or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by this Agreement; and 
 (vi) (A) The Registration Statement shall remain effective at all times up to and including the Closing Date and the issuance of the Shares to the Investor may be made thereunder; (B) neither the Company nor the Investor shall have
received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement or that the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement either,
temporarily or permanently, or intends or has threatened to do so; and (C) no other suspension of the use or withdrawal of the effectiveness of the Registration Statement or Prospectus shall exist. 
 (b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase the Shares shall be subject to: 

(i) the Investor’s receipt of the Company’s executed signature page to this Agreement; 
 (ii) the accuracy of the representations and warranties made by the Company and the fulfillment of those undertakings of the Company to be fulfilled
prior to the Closing Date; 
 (iii) the Company shall have obtained all governmental, regulatory or third party consents and approvals, if
any, necessary for the sale of the Shares, including without limitation, those required by Nasdaq; 
 (iv) no statute, rule, regulation,
executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by this
Agreement; and 
 (v) (A) The Registration Statement shall remain effective at all times up to and including the Closing Date and the
issuance of the Shares to the Investor may be made thereunder; (B) neither the Company nor the Investor shall have received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement or
that the Commission otherwise has suspended or withdrawn the effectiveness of the Registration Statement either, temporarily or permanently, or intends or has threatened to do so; and (C) no other suspension of the use or withdrawal of the
effectiveness of the Registration Statement or Prospectus shall exist. 
  

 - 6 - 

 The Investor’s obligations are expressly not conditioned on the purchase by any or all of the Other
Investors of the Shares that they have agreed to purchase from the Company. 
 3.3 Delivery of Funds. 
 (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such Investor through DTC’s Deposit/Withdrawal at Custodian
(“DWAC”) delivery system, no later than one (1) business day after the execution of this Agreement by the Investor and the Company, the Investor shall remit by wire transfer the amount of funds equal to the
aggregate purchase price for the Shares being purchased by the Investor to the following account designated by the Company: 
 Bank of
America 
 Address: 
 ABA #

 Account Name: 
 Account Number:

 Attention: 
 Phone: 

Facsimile: 
 Such funds shall be deemed to be held in
escrow until the Closing, at which time such funds will be deemed released to the Company. 
 (b) Delivery Versus Payment through The
Depository Trust Company. If the Investor elects to settle the Shares purchased by such Investor by delivery versus payment through DTC, no later than one (1) business day after the execution of this Agreement by the Investor and the
Company, the Investor shall confirm that the account or accounts at the Institution to be credited with the Shares being purchased by the Investor have a minimum balance equal to the aggregate purchase price for the Shares being purchased by
the Investor. 
 3.4 Delivery of Shares. 
 (a) DWAC Delivery. If the Investor elects to settle the Shares purchased by such Investor through DTC’s DWAC delivery system, no later than one (1) business day after the execution of this
Agreement by the Investor and the Company, the Investor shall direct the broker-dealer at which the account or accounts to be credited with the Shares being purchased by such Investor are maintained, which broker/dealer shall be a DTC
participant, to set up a DWAC instructing American Stock Transfer & Trust Company, the Company’s Transfer Agent, to credit such account or accounts with the Shares. Such DWAC instruction shall indicate the settlement date for the
deposit of the Shares. Simultaneously with the release to the Company of the funds held in escrow pursuant to Section 3.3 above, the Company shall direct the Transfer Agent to credit the Investor’s account or accounts with the
Shares pursuant to the information contained in the DWAC. 
 (b) Delivery Versus Payment through The Depository Trust Company.
If the Investor elects to settle the Shares purchased by such Investor by delivery versus payment through DTC, no later than one (1) business day after the execution of this Agreement by the Investor and the Company, the Investor
shall notify the Institution of the account or accounts at the Institution to be credited with the Shares being purchased by such Investor. On the Closing Date, the Company shall deliver the Shares to the Investor through DTC directly to the
account(s) at the Institution identified by Investor and simultaneously therewith payment shall be made by the Institution by wire transfer to the Company. 
  

 - 7 - 

 4. Representations, Warranties and Covenants of the Investor. 
 The Investor acknowledges, represents and warrants to, and agrees with, the Company that: 
 4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to,
investments in shares presenting an investment decision like that involved in the purchase of the Shares, including investments in securities issued by the Company and investments in comparable companies, (b) has answered all questions on the
Signature Page and the Investor Questionnaire and the answers thereto are true and correct as of the date hereof and will be true and correct as of the Closing Date and (c) in connection with its decision to purchase the number of Shares set
forth on the Signature Page, has received and is relying only upon the Disclosure Package and the documents incorporated by reference therein and the Offering Information. 
 4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by the Company that would permit an offering of the
Shares, or possession or distribution of offering materials in connection with the issue of the Shares in any jurisdiction outside the United States where action for that purpose is required, (b) if the Investor is outside the United States, it
will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense and (c) the
Company has not made any representation, disclosure or use of any information in connection with the issue, placement, purchase and sale of the Shares, except as set forth or incorporated by reference in the Base Prospectus or the Prospectus
Supplement. 
 4.3 (a) The Investor has full right, power, authority and capacity to enter into this Agreement and to consummate
the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement constitutes a valid and binding obligation of the Investor enforceable
against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and
except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 4.4 The Investor understands that nothing in this Agreement, the Prospectus or any other materials presented to the Investor in connection with the purchase and sale of the Shares constitutes legal, tax or
investment advice. The Investor has consulted such legal, tax and investment advisors and made such investigation as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares. 
 4.5 Since the time at which the Company first contacted the Investor about the Offering, the Investor has not disclosed any information regarding
the Offering to any third parties (other than its legal, accounting and other advisors) and has not engaged in any transactions involving the securities of the Company (including, without limitation, any Short Sales involving the Company’s
securities). The Investor covenants that it will not engage in any purchases or sales of the securities of the Company (including Short Sales) prior to the time that the transactions contemplated by this Agreement are publicly disclosed. The
Investor agrees that it will not use any of the Shares acquired pursuant to this Agreement to cover any short position in the Common Stock if doing so would be in violation of applicable securities laws. For purposes hereof, “Short
Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether or not
against the box, and all types of direct and indirect stock pledges, forward sales contracts, options, puts, calls, short sales, swaps, “put equivalent 

  

 - 8 - 

 
positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other
transactions through non-US broker dealers or foreign regulated brokers. 
 5. Representations, Warranties and Covenants of the Company.

 5.1 Organization and Qualification. The Company is duly organized and validly existing and in good standing under the
laws of the State of Delaware, and has the requisite power and authorization to own its properties and to carry on its business as now being conducted and as presently proposed to be conducted. The Company is duly qualified as a foreign entity to do
business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good
standing would not have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof) or
condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, (ii) the legality, validity or enforceability of the transactions contemplated hereby or (iii) the authority or ability of the Company to perform its
obligations hereunder. 
 5.2 Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority
to enter into and perform its obligations under this Agreement and to issue the Shares in accordance with the terms hereof. The execution and delivery of this Agreement by the Company, and the consummation by the Company of the transactions
contemplated hereby have been duly authorized by the Company’s board of directors and, other than the filing with the Commission of a the Prospectus Supplement relating to the transactions contemplated hereby, no further filing, consent or
authorization is required by the Company, its board of directors or its stockholders or other governing body or regulatory authority. This Agreement has been duly executed and delivered by the Company and constitutes a valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting
parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 5.3 Issuance of Shares. The issuance of the Shares is duly authorized and, when issued and paid for in accordance with the terms of this
Agreement, the Shares shall be validly issued, fully paid and non-assessable and free from all taxes, liens, charges and other encumbrances imposed by the Company. The Company has available for issuance and sale from its duly authorized capital
stock the Shares issuable pursuant to this Agreement. The Shares are being issued pursuant to the Registration Statement and the issuance of the Shares has been registered by the Company under the Securities Act. The Registration Statement is
effective and available for the issuance of the Shares thereunder and the Company has not received any notice that the Commission has issued or intends to issue a stop-order or other order with respect to the Registration Statement or the Prospectus
or that the Commission otherwise has (i) suspended or withdrawn the effectiveness of the Registration Statement or (ii) issued any order preventing or suspending the use of the Prospectus, in either case, either temporarily or permanently,
or intends or has threatened in writing to do so. The “Plan of Distribution” section under the Registration Statement permits the issuance of the Shares hereunder. At the time the Registration Statement and any amendments thereto became
effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the
Prospectus or any amendment or supplement thereto was issued and at the Closing Date, 

  

 - 9 - 

 
conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 5.4 No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the
transactions contemplated hereby will not (i) result in a violation of the Company’s Restated Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”), or the
Company’s bylaws, as amended and as in effect on the date hereof (the “Bylaws”), (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its subsidiaries is a party, or (iii) subject to the making of the Required Filings (as defined below)
by the Company, result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and regulations of Nasdaq) applicable to the Company or any of its
subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such violations that could not reasonably be expected to have a
Material Adverse Effect. 
 5.5 Consents. The Company is not required to obtain any consent, authorization or order of, or make
any filing or registration with, any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement, other than
(i) a notification filing with Nasdaq, (ii) the filing with the Commission of the Prospectus Supplement and (iii) the filing with the Commission of a Current Report on Form 8-K (collectively, “Required Filings”). All
consents, authorizations, orders, filings and registrations which the Company is required to obtain or make on or before the Closing Date pursuant to the preceding sentence have been obtained or made on or prior to the Closing Date. Required Filings
to be made after the Closing Date shall be made in compliance with the terms of this Agreement and applicable federal and state securities laws. 
 5.6 SEC Documents. During the one (1) year prior to the date hereof, the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the Commission pursuant to
the reporting requirements of the Exchange Act (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being
referred to herein as the “SEC Documents”). As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder
applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance with generally accepted
accounting principles, consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they
may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate). 
  

 - 10 - 

 5.7 Absence of Certain Changes. Since the date of the Company’s most recent financial
statements contained in its Form 10-Q for the quarter ended August 1, 2009 (the “Form 10-Q”), except as disclosed in subsequent SEC Documents filed prior to the date hereof, there has been no event, occurrence or development
that, individually or in the aggregate, has had or would reasonably be expected to result in a Material Adverse Effect. Since the date of the Company’s most recent financial statements contained in the Form 10-Q, except as disclosed in a
subsequent SEC Documents filed prior to the date hereof, neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends other than by Subsidiaries to the Company or (ii) sold any material assets, individually or in
the aggregate, outside of the ordinary course of business. 
 5.8 Compliance. Neither the Company nor any of its subsidiaries
(i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its subsidiaries under), nor has the Company or any of
its subsidiaries received written notice of a claim that it is in default under or that it is in violation of, any material agreement of the Company (whether or not such default or violation has been waived), (ii) is in violation of any order
of which the Company or any of its subsidiaries has been made aware in writing of any court, arbitrator or governmental body having jurisdiction over the Company or any of its subsidiaries or their respective properties or assets, or (iii) is
in violation of, or in receipt of written notice that it is in violation of, any statute, rule or regulation of any governmental authority applicable to the Company or any of its subsidiaries, except in each case as would not have or reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect. 
 6. Survival of Representations, Warranties and
Agreements; Third Party Beneficiary. Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investor herein will survive the execution of this
Agreement, the delivery to the Investor of the Shares being purchased and the payment therefor for a period of one (1) year from the date hereof. 
 7. Notices. All notices, requests, consents and other communications hereunder will be in writing, will be mailed (a) if within the domestic United States by first-class registered or certified airmail, or
nationally recognized overnight express courier, postage prepaid, or by facsimile or (b) if delivered from outside the United States, by International Federal Express or facsimile, and (c) will be deemed given (i) if delivered by
first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express,
two business days after so mailed and (iv) if delivered by facsimile, upon electric confirmation of receipt and will be delivered and addressed as follows: 
 (a) if to the Company, to: 
 Casual Male Retail Group, Inc. 
 555 Turnpike Street 
 Canton, Massachusetts
02021 
 Attention: Robert S. Molloy 
 Facsimile: (781) 821-5174 
 with a copy (which shall not constitute notice) to: 
 Greenberg Traurig LLP 
 One International
Place 
 Boston, Massachusetts 02110 
 Attention: Bradley A. Jacobson 
 Facsimile: (617) 279-8402 
  

 - 11 - 

 (b) if to the Investor, at its address on the Signature Page hereto, or at such other address or
addresses as may have been furnished to the Company in writing. 
 8. Changes. This Agreement may not be modified or amended except
pursuant to an instrument in writing signed by the Company and the Investor. 
 9. Headings. The headings of the various sections of
this Agreement have been inserted for convenience of reference only and will not be deemed to be part of this Agreement. 
 10. Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in
any way be affected or impaired thereby. 
 11. Governing Law. This Agreement will be governed by, and construed in accordance with,
the internal laws of the State of Delaware, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction. 
 12. Counterparts. This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when
taken together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 
 13. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s receipt of the Company’s signed counterpart to this
Agreement, together with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission), shall constitute written confirmation of the Company’s sale of Shares to such Investor. 
 14. Press Release. The Company and the Investor agree that the Company shall issue a press release announcing the Offering and disclosing all
material information regarding the Offering prior to the opening of the financial markets in New York City on the business day immediately after the date hereof. 
 15. Publicity. The Company agrees that it will not use in advertising or publicity the names of the Investor, Fidelity Management & Research Company, any of its partners or employees, any of the funds
or accounts managed by it or any of its affiliates, or any trade name, trademark, trade device, service mark, symbol or any abbreviation, contraction or simulation thereof, in any case without the prior written consent of Fidelity
Management & Research Company, except for public disclosure required by federal securities laws in connection with the filing of final Agreements with the Commission. 
 16. Limitation of Liability. A copy of the Agreement and Declaration of Trust of the Investor is on file with the Secretary of State of the
Investor’s formation, and notice is hereby given that this Agreement is not executed on behalf of the Trustees of the Investor as individuals and that the obligations of this Agreement are not binding upon any of the Trustees, officers or
stockholders of the Investor individually but are binding only upon the assets and property of such Investor. The Company is expressly put on notice that the rights and obligations of each series of shares of each trust under the Investor’s
Declaration of Trust are separate and distinct from those of any and all other series. 
 17. Termination. This Agreement may be
terminated and the sale and purchase of the Shares hereunder abandoned at any time prior to the Closing by either the Company or the Investor upon written 

  

 - 12 - 

 
notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m., New York City time, on the tenth (10th) day following the date of this Agreement; provided, however, that the right to terminate
this Agreement under this Section 15 shall not be available to any person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time.

  

 - 13 - 

 EXHIBIT A 
 CASUAL MALE RETAIL GROUP, INC. 
 INVESTOR QUESTIONNAIRE 
 Pursuant to Section 3 of Annex I to the Agreement, please provide us with the following information: 
  

					
	1.	  	The exact name that your Shares are to be registered in. You may use a nominee name if appropriate:	  	
			
	2.	  	The relationship between the Investor and the registered holder listed in response to item 1 above:	  	
			
	3.	  	The mailing address of the registered holder listed in response to item 1 above:	  	
			
	4.	  	The Social Security Number or Tax Identification Number of the registered holder listed in the response to item 1 above:	  	
			
	5.	  	Name of DTC Participant (broker-dealer at which the account or accounts to be credited with the Shares are maintained):	  	
			
	6.	  	DTC Participant Number:	  	
			
	7.	  	Name of Account at DTC Participant being credited with the Shares:	  	
			
	8.	  	Account Number at DTC Participant being credited with the Shares:	  	

  

 - 14 -First Modification, Waiver and Acknowledgement Agreement

 Exhibit 10.1 
 FIRST MODIFICATION, WAIVER AND ACKNOWLEDGEMENT AGREEMENT 
 This First Modification, Waiver and
Acknowledgement Agreement (“Agreement”) dated as of August 29, 2009 is entered into by and among Commonwealth Biotechnologies Inc., a Virginia corporation (the “Company”) and Fornova Pharmaworld, Ltd (Fornova) the Note
Holder identified on the signature page. 
 WHEREAS, the Company and Fornova are parties to a Convertible Note dated August 29, 2008,
relating to an aggregate purchase of $500,000 of principal amount of secured promissory notes (the “Notes”) of the Company convertible into shares of the Company’s no par value common stock; and 
 WHEREAS, the Company and Fornova desire to further restructure the terms of the Notes to their mutual benefit. 
 NOW THEREFORE, in consideration of the mutual covenants and other agreements contained in this Agreement, the Company and Fornova hereby agree as
follows: 
 1. Capitalized terms employed herein shall have the meanings attributed to them in the Notes. 
 2. The Maturity Date of the Notes, which are due to mature on August 28, 2009 is extended to January 1, 2010. 
 3. The Company undertakes to use its best efforts to immediately file a proxy statement for shareholder approval to reduce the Conversion Price of the
Notes to $0.50. In the event shareholder approval is not obtained, the Conversion Price will not be reduced to $0.50. 
 4. All interest
which has accrued through August 28, 2009 shall be deferred until December 31, 2009 and shall be payable pursuant to the terms of the Notes. 
 5. The Company acknowledges that the holding period of the Notes and Common Stock issuable upon conversion of the Notes commenced on August 29, 2008, for purposes of Rule 144 under the Securities Act of 1933.

 6. The Company undertakes to make a public announcement on Form 8-K describing the terms of this Agreement not later than the fourth
business day after the execution of this Agreement. 
 7. For the benefit of the parties hereto, the Company hereby makes all the
representations, warranties, covenants undertakings and indemnifications contained in the Notes, as if such representations were made by the Company as of this date. 
 8. Subject to the modifications and amendments provided herein, the Notes shall remain in full force and effect, including but not limited to the accrual of interest and liquidated damages, if any. Except as expressly
set forth herein, this Agreement shall not be deemed to be a waiver, amendment or modification of any provisions of the Notes or of any right, power or remedy of Fornova, or constitute a waiver of any provision of the Notes (except to the extent
herein set forth), or any other document, instrument and/or agreement executed or delivered in connection therewith, in each case whether arising before or after the date hereof or as a result of performance hereunder or thereunder. Except as set
forth herein. Fornova reserve all rights, remedies, powers, or privileges available under the Notes, at law or otherwise. This Agreement shall not constitute a novation or satisfaction and accord of the Notes or any other document, instrument and/or
agreement executed or delivered in connection therewith. 

 9. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties: provided, however, that no party may assign this Agreement or the obligations and rights of such party hereunder without the prior written consent of the other parties hereto, except as same is permitted under
the Notes. 
 10. This Agreement constitutes the entire agreement among the parties regarding the subject matter herein, and supersedes all
prior and contemporaneous agreements and understandings of the parties in connection herewith. No changes, modifications, terminations or waivers of any of the provisions hereof shall be binding unless in writing and signed by all of the parties
thereto. 
 11. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
pursuant to the governing law provisions of the Notes. 
 12. The language used in this Agreement will be deemed to be the language chosen by
the parties to express their mutual intent, and no rules of strict construction will be applied against any party. 
 13. Each of the
undersigned states that he has read the foregoing Agreement and understands and agrees to it. 
 14. This Agreement may be executed in two or
more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to any other party, it being understood that all parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or electronically, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature were an original thereof. 
 [Signature Page Follows]

 IN WITNESS WHEREOF, the undersigned have executed and delivered this Modification. Waiver and
Acknowledgement Agreement as of the date first written above. 
  

			
	COMMONWEALTH BIOTECHNOLOGIES INC.
	the “Company”
		
	By:	 	

	Name:	 	Richard J. Freer
	Title:	 	COO    8/29/09
	
	“HOLDER”
	
	Fornova Pharmaworld, Ltd
		
	By:	 	

	Name:	 	Dezheng Li
	Title:	 	29/8/09

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]